Halozyme Therapeutics (NASDAQ: HALO) reported Q1 EPS of $1.11, $0.13 better than the analyst estimate of $0.98. Revenue for the quarter came in at $265 million versus the consensus estimate of $229.29 million.

GUIDANCE:

Halozyme Therapeutics sees FY2025 EPS of $5.30-$5.70, versus the consensus of $5.00. Halozyme Therapeutics sees FY2025 revenue of $1.2-1.28 billion, versus the consensus of $1.191 billion.

For earnings history and earnings-related data on Halozyme Therapeutics (HALO) click here.